Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,031
  • Shares Outstanding, K 55,911
  • Annual Sales, $ 47,980 K
  • Annual Income, $ -68,570 K
  • EBIT $ -73 M
  • EBITDA $ -73 M
  • 60-Month Beta 0.23
  • Price/Sales 0.80
  • Price/Cash Flow N/A
  • Price/Book 1.14
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.28
  • Most Recent Earnings $-0.25 on 05/13/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 344.17% ( -168.18%)
  • Historical Volatility 77.08%
  • IV Percentile 51%
  • IV Rank 28.55%
  • IV High 1,123.49% on 05/15/25
  • IV Low 32.70% on 07/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 225
  • Volume Avg (30-Day) 81
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 1,572
  • Open Int (30-Day) 979

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.32
  • Number of Estimates 1
  • High Estimate -0.32
  • Low Estimate -0.32
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5700 +20.32%
on 05/09/25
0.7828 -12.39%
on 04/22/25
-0.0392 (-5.41%)
since 04/21/25
3-Month
0.5052 +35.75%
on 04/09/25
0.9200 -25.46%
on 03/25/25
-0.1452 (-17.47%)
since 02/21/25
52-Week
0.5052 +35.75%
on 04/09/25
1.5300 -55.18%
on 07/16/24
-0.8242 (-54.58%)
since 05/21/24

Most Recent Stories

More News
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

SPRO : 0.6858 (+0.82%)
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

SPRO : 0.6858 (+0.82%)
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

SPRO : 0.6858 (+0.82%)
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

SPRO : 0.6858 (+0.82%)
Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

SPRO : 0.6858 (+0.82%)
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

SPRO : 0.6858 (+0.82%)
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

SPRO : 0.6858 (+0.82%)
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

SPRO : 0.6858 (+0.82%)
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

Shares of small biotech Arcutis Biotherapeutics ARQT have surged nearly three times in market value in the past year.The upside has been primarily driven by the positive regulatory updates regarding the...

CTMX : 2.04 (-0.97%)
CSTL : 16.02 (-2.91%)
ARQT : 13.76 (-5.17%)
SPRO : 0.6858 (+0.82%)
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGVHD)...

MESO : 11.26 (-2.43%)
CTMX : 2.04 (-0.97%)
CSTL : 16.02 (-2.91%)
SPRO : 0.6858 (+0.82%)

Business Summary

Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 0.7398
2nd Resistance Point 0.7267
1st Resistance Point 0.7063
Last Price 0.6858
1st Support Level 0.6728
2nd Support Level 0.6597
3rd Support Level 0.6393

See More

52-Week High 1.5300
Fibonacci 61.8% 1.1385
Fibonacci 50% 1.0176
Fibonacci 38.2% 0.8967
Last Price 0.6858
52-Week Low 0.5052

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar